Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAVELIN Renal 101: Avelumab + Axitinib vs Sunitinib in Advanced RCC
NCT02684006Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2016
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
A Phase 3 trial of avelumab in renal cell carcinoma (RCC), sponsored by Pfizer. Started Mar 2016; status: completed.
02
Drugs
avelumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02684006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02684006.